Characteristics of participants according to whether they accepted or declined germline testing for Lynch syndrome
| Characteristic | No. (%) of participants | |
|---|---|---|
| Accepted germline testing n = 98 | Declined germline testing n = 21 | |
| Age at diagnosis, yr | ||
| ≤ 50 | 14 (14) | 1 (5) |
| > 50 | 84 (86) | 20 (95) |
| Body mass index at diagnosis | ||
| 18.5–24.9 | 16 (16) | 2 (10) |
| 25.0–29.9 | 18 (18) | 4 (19) |
| 30.0–34.9 | 25 (26) | 5 (24) |
| 35.0–39.9 | 11 (11) | 4 (19) |
| ≥ 40.0 | 28 (29) | 6 (29) |
| Histologic type | ||
| Endometrioid | 81 (83) | 17 (81) |
| Clear cell | 1 (1) | 2 (10) |
| Serous | 3 (3) | 2 (10) |
| Mixed carcinoma | 5 (5) | 0 (0) |
| Malignant mixed müllerian tumour | 3 (3) | 0 (0) |
| Other | 5 (5) | 0 (0) |
| FIGO grade | ||
| 1 | 49 (50) | 9 (43) |
| 2 | 18 (18) | 7 (33) |
| 3 | 31 (32) | 5 (24) |
| FIGO stage | ||
| 1 | 73 (74) | 14 (67) |
| 2 | 4 (4) | 2 (10) |
| 3 | 16 (16) | 3 (14) |
| 4 | 2 (2) | 1 (5) |
| Unable to stage | 3 (3) | 1 (5) |
| Loss of MMR protein expression | ||
| Yes | 72 (74) | 19 (90) |
| No | 26 (26) | 2 (10) |
| Family history of Lynch-associated cancer | ||
| Yes | 50 (51) | 7 (33) |
| No | 46 (47) | 12 (57) |
| Unknown | 2 (2) | 2 (10) |
| Personal history of Lynch-associated cancer* | ||
| Yes | 18 (18) | 1 (5) |
| No | 80 (82) | 18 (86) |
| Unknown | 0 (0) | 2 (10) |
Note: FIGO = International Federation of Gynaecology and Obstetrics, MMR = mismatch repair.
↵* Excluding endometrial cancer.